The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)

Background Several studies have shown that combining immune checkpoint inhibitors (ICIs) with antiangiogenic tyrosine kinase inhibitors is effective for solid tumors, including esophageal squamous cell carcinoma (ESCC). However, most of these studies were focused on immunotherapy-naive patients. Thi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xueru Zhu, Xiumei Ma, Hongxuan Li, Ming Zhang, Yan Cheng, Jianguo Wu, Wen Yu, Wen Feng, Lei Zhao, Zhigang Li, Xiaolong Fu, Jun Liu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2025-12-01
Colecção:	Annals of Medicine
Assuntos:	Anlotinib combination therapeutic regimen esophageal squamous cell carcinoma PD-1 inhibitor progressed on prior ICI
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2443811
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!